UTMB Sealy Center for Vaccine Development

With more than 75 members the Sealy Center for Vaccine Development (SCVD) incorporates the expertise of more than 100 cutting-edge research programs. The faculty and staff of the SCVD strive to create, perfect, and promote the most effective and safest disease prevention strategies. In this effort, the center carries on the proud tradition of medical research and discovery that has been a hallmark of UTMB since its inception. The SCVD combines the expertise of basic scientists in many areas, including virologists, bacteriologists, parasitologists, materials scientists and immunologists, and physician-scientists who undertake clinical research and regulatory scientists with experience necessary to prepare a candidate vaccine for progression into the testing and evaluation pipeline. As one of the most comprehensive university-based vaccine development centers in the US, the SCVD participates in four out of the five components (excluding manufacturing) of the vaccine development pathway: • Basic & Discovery Research Vaccines for infectious diseases, including chronic diseases Biothreat agents, BSL2-4 • Pre/Nonclinical Development Animal models of infectious diseases Regulated studies and quality systems • Clinical Research and Trials Phase I-IV vaccine clinical trials Federal and Pharma studies • Post-licensure Policy and vaccine acceptance research Public and healthcare provider education